ABSTRACT
Niveles circulantes de adipoquinas en sujetos no diabéticos con presión arterial normal-alta
Adipokines contribute to adipocyte metabolism and function; they modulate and regulate different biological processes such as insulin resistance, inflammation, and the risk of developing metabolic and cardiovascular complications. When adipose tissue dysfunction has developed, adipokine secretion is significantly changed toward a diabetogenic, proinflammatory and atherogenic pattern (1) .
Adiponectin and resistin modulate insulin action; adiponectin improves insulin sensitivity and has anti-inflammatory properties, whereas resistin is associated with insulin resistance and metabolic syndrome; this adipokine impairs endothelial function and has proinflammatory effects (2) .
Hypoadiponectinaemia has been reported as a risk factor for the development of cardiovascular disease (3), and hyperrestinaemia is associated with pathways that lead to atherosclerosis and cardiovascular disease (4) .
Borderline hypertension is defined by the Mexican regulations as the presence of systolic blood pressure (BP) between 130 mmHg and 139 mmHg and⁄or a diastolic BP between 85 mmHg and 89 mmHg (5) . These values of blood pressure are referred to as high normal blood pressure (HNBP), by the 2013 European Society for Hypertension/European Society for Cardiology Guidelines for the Management of Arterial Hypertension [ESG] (6).
Cardiovascular risk increases at systolic BP of 130 and diastolic BP of 85 mmHg. In fact, individuals with BP values in the range of HNBP, enrolled in the Strong Heart Study, showed a two-fold higher prevalence of left ventricular hypertrophy than their normotensive counterparts (7) . Although the associated cardiovascular risk in those patients is unclear, evidence suggests that people with BP in the HNBP range may be at increased cardiovascular risk. Those subjects also show increased carotid artery intimal-media thickness and arterial stiffness (8) .
The aim of this study was to evaluate circulating levels of theadipokines, adiponectin and resistin in non-diabetic patients with HNBP.
SUBJECTS AND METHODS
The study comprised 20 non-diabetic patients with HNBP (as defined by 2013 ESG) and 20 age-matched normotensive controls.
Venous samples were collected in the morning after a 12-hour overnight fast. Circulating levels of adiponectin and resistin were measured in duplicate using commercially available enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN, USA), following manufacturer´s recommendations. Enzyme-linked immunosorbent assays were performed by personnel blinded to the study. Intra-assay coefficient of variability (CV) for adiponectin was 3.4% and inter-assay CV was 5.8%, whereas intra-assay CV for resistin was 5.5% and inter-assay CV was 9.2%.
Patients with any of the following diagnoses were excluded from the study: diabetes mellitus [according to the American Diabetes Association criteria] (9); heart, hepatic, or renal failure; evidence of valvular heart disease, heart block or cardiac arrhythmia, acute coronary syndrome or cerebrovascular disease six months before the study's initiation; autoimmune disease; pregnancy; urinary tract infection; fever, or a history of alcohol abuse and/or psychotropic drugs.
The study was conducted with the approval of the Research and Medical Ethics Committee of our hospital, in accordance with the Declaration of Helsinki. Participants gave written informed consent before their inclusion in the study protocol. Statistical analysis was formed with analysis of variance test. p < 0.05 was considered as statistically significant.
RESULTS
The basal characteristics of the patients and controls are shown in Table 2 . The HNBP group showed a non-significant increase in the levels of resistin when compared with controls (14.38 vs 12.25 pg/mL, p = 0.40). There were significantly lower levels of adiponectin in HNBP (7.51 vs 11.3 μg/mL, p = 0.028), when compared with the age-matched normotensive controls (Figure) . Figure: Adipokine levels in patients and controls.
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DISCUSSION
In this study, HNBP non-diabetic patients had higher circulating levels of resistin and lower adiponectin than normotensive controls. The methodology was strengthened by duplicate determinations of adipokines, so intra-individual variation was taken into account, and the exclusion of diabetic patients, since diabetes mellitus may modify adipokine levels with potential interference in the analysis of the results (10) . Both hypoadiponectinaemia and hyperresistinaemia are associated with the coexistence of hypertension and Type 2 diabetes (2). Kawamoto et al found that high molecular weight adiponectin levels correlated with blood pressure in men, but not women (11) ; however, in their study, resistin levels were not assessed. Patients with BP values in the range of HNBP have a higher risk to develop hypertension than normotensive patients (12) . But whether the progression from HNBP to hypertension is dependent (solely or in part) on adipokine levels requires further investigation.
Papadopoulos et al (13) found that patients with prehypertension had significantly higher resistin plasma levels and significantly lower adiponectin plasma levels than healthy normotensive subjects, whereas in our study, although adiponectin levels were significantly lower in HNBP, no difference was found in resistin levels between groups. It is important to note that the patients in the present study had a greater body mass index than those from the study of Papadopoulos.
Besides a possible role in the progression from HNBP to hypertension, the results may have prognostic implications. Data from the Framingham study indicated that BP values in the range of HNBP are associated with a two-fold increase in the risk of cardiovascular disease when compared with normotensive patients (14) . Patients with BP values in that range also show increased carotid artery intimal-media thickness (9) . Indeed hypoadiponectinaemia and hyperresistinaemia are associated with a higher risk for the development of cardiovascular disease, and both resistin and the adiponectin/resistin index (which includes information about the circulating levels of both adipokines), correlate with the carotid intima-media thickness (4). Our findings may explain, at least in part, the pathways that lead to the increased cardiovascular risk in patients with HNBP.
In conclusion, patients with high normal blood pressure have lower values of adiponectin, and non-significantly higher levels of resistin than non-diabetic normotensive subjects. This may explain why those patients with HNBP show more atherosclerosis and cardiovascular risk than normotensive subjects.
